<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Familial partial <z:hpo ids='HP_0009125'>lipodystrophy</z:hpo> (FPLD) is a rare <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorder</z:e> with clinical features that may not be readily recognised </plain></SENT>
<SENT sid="1" pm="."><plain>As FPLD patients require a specific therapeutic approach, early identification is warranted </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study we aimed to identify cases of FPLD among non-<z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and marked <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We searched the databases of three diabetic outpatient clinics for patients with marked <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, arbitrarily defined as the use of ≥100 U insulin/day, and BMI ≤ 27 kg/m(2) </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> patients, metabolic variables and anthropomorphic measurements were evaluated and DNA was sequenced for mutations in the genes encoding lamin A/C (LMNA), peroxisome proliferator-activated receptor γ (PPARγ) and cell <z:hpo ids='HP_0011420'>death</z:hpo>-inducing DFFA-like effector c (CIDEC) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Out of 5,221 diabetic individuals, 24 patients fulfilled <z:hpo ids='HP_0000001'>all</z:hpo> criteria </plain></SENT>
<SENT sid="6" pm="."><plain>Twelve patients were willing to participate, of whom five showed clinical features of <z:hpo ids='HP_0009125'>lipodystrophy</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>In three of these patients the clinical diagnosis of FPLD was confirmed by the presence of mutations in LMNA or PPARG; one patient harboured a novel heterozygous mutation (Y151C) in PPARG </plain></SENT>
<SENT sid="8" pm="."><plain>The Y151C mutant displayed impaired DNA-binding capacity and hence reduced transcriptional activity compared with <z:mp ids='MP_0002169'>wild-type</z:mp> PPARγ </plain></SENT>
<SENT sid="9" pm="."><plain>Dominant-negative activity was absent </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION/INTERPRETATION: The combination of BMI ≤ 27 kg/m(2) and the use of &gt;100 U insulin/day increases the chance of identifying <z:hpo ids='HP_0009125'>lipodystrophy</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Thus careful assessment of clinical features of FPLD should be considered in these patients, allowing earlier therapeutic interventions </plain></SENT>
</text></document>